- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00708786
Ventricular Arrhythmias Incidence According to Sleep Apnea Syndrome in Implantable Cardioverter-Defibrillator (ICD) Patients
June 30, 2008 updated by: LivaNova
Ventricular Arrhythmias Incidence According to Sleep Apnea Syndrome in ICD Patients
The purpose of this study is to report the incidence of ventricular arrhythmias correlated to the SAS and to focus on the interest of diagnosing Sleep-disorders breathing in ICD patients.
This diagnosis will be assessed by an ambulatory nasal pressure recording with portable multi-channel recorder associated to a complete SAS related symptoms questionnaire.This clinical trial will be the first step to gather information about the suspected sleep relation between ventricular arrhythmias and Sleep breathing disorders, in order to improve the management and treatment of such arrhythmias in next generation of defibrillators which will integrate a minute ventilation sensor able to monitor breathing.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
755
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brest, France
- CHRU Hôpital de la Cavale Blanche
-
Clermont Ferrand, France
- CHU
-
Grenoble, France, 38043
- CHU - Hopital Michallon
-
Limoges, France
- CHU Dupuytren
-
Lyon, France
- Hopital Saint Joseph et saint Luc
-
Lyon, France
- Hopital Cardiologique
-
Marseille, France
- Hopital Nord
-
Metz, France
- CHR Notre Dame de Bonsecours
-
Montpellier, France
- CH Montpellier
-
Nantes, France
- Nouvelle Clinique Nantaise
-
Paris, France
- Clinique Bizet
-
Paris cedex 16, France, 75116
- Clinique Bizet
-
Pau, France
- CH Pau
-
Poitiers, France
- CHU Hopital la Milétrie
-
Rennes, France
- CHR Cardiologie A
-
Rouen, France
- CHU Charles Nicolle
-
Toulouse, France
- Clinique Pasteur
-
Tours, France
- Clinique Saint Gatien
-
Tours, France
- CHRU Hopital Trousseau
-
Vandoeuvre les Nancy, France
- Chru Brabois
-
-
-
-
-
Bad Bevensen, Germany
- Herz-Kreislauf-Klinik Bevensen AG
-
Hamburg, Germany
- Universitätsklinikum Hamburg Eppendorf
-
Starnberg, Germany
- Prof. Frey Praxis Starnberg
-
-
-
-
-
Athens, Greece
- Onassis Cardiac Surgery Center
-
-
-
-
-
Chiari (BS), Italy
- Ospedale Mellini
-
Desio, Italy
- Osp. Civile
-
Mercogliano, Italy
- Casa di Cura Montevergine
-
Modenna, Italy
- Policlinico de Modenna
-
Pavia, Italy
- Instituto di Cura
-
Piacenza, Italy
- Hospitale civile Guglielmo da Saliceto
-
San Donato, Italy
- Policlínico San Donato
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who are at risk of sudden death due to ventricular arrhythmia and who satisfy at least one of the following criteria are eligible for enrolment:
Class I indications for ICD
- Survival of at least one episode of cardiac arrest due to VT or VF not due to a transient or reversible cause, or presumed to be due to VF when electrophysiological testing is precluded by other medical conditions; or
- Spontaneous sustained ventricular tachycardia, or
- Syncope of undetermined origin with clinically relevant haemodynamically significant sustained VT or VF induced at electrophysiological study when drug therapy is ineffective, not tolerated or not preferred, or
Class IIa Indication for ICD
- Non-sustained VT with coronary disease, prior myocardial infarction, left ventricular dysfunction (≤ 40%) and inducible VF or sustained VT at electrophysiological study.
- With prior myocardial infarction and LVEF less than 30 % (without prior life-threatening arrhythmia or sustained VT).
- Patients candidate for cardiac resynchronization therapy (CRT) need to be in functional Class III or IV of the NYHA classification.
Patients will be included only after having granted their informed consent to participate in the study, preceded by the delivery of appropriate information
Exclusion Criteria:
- VT/VF is associated with drug toxicity, electrolyte imbalance, hypoxia, electrocution or other reversible cause;
- VT/VF occurred during the acute phase of infarction (< 1 week) or during an unstable ischemic phase;
- Incessant VT/VF;
- Implanted pacemaker that is not going to be explanted or otherwise disabled;
- Inability or refusal to provided informed consent
- Tricuspid valvular disease or tricuspid mechanical heart valve (lead contraindication);
- Unable to understand the purpose and plan of the study;
- Geographically unstable or not available for follow-up as defined in the investigational plan;
- Reduced life expectancy (≤ 1 year) for other than cardiovascular reasons;
- Patient participating in another clinical study;
- Patient of minor age (< 18 years);
- Pregnancy (Women of childbearing potential are required to have a negative pregnancy test within seven days prior to enrollment).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objective of this study is to assess the correlation between ventricular arrhythmias and Sleep apnoea syndrome in ICD patients during a 12-month follow-up.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the number of arrhythmias in the morning (between 06:00 and 12:00 AM). The circadian distribution of global arrhythmias will be presented.
Time Frame: 12 months
|
12 months
|
To report and compare the number of hospitalizations, mortality, and morbidity according to Respiratory Disturbance Index (RDI).
Time Frame: 12 months
|
12 months
|
To evaluate the incidence of adverse events in the studied population: device-related adverse events with an actual or potential effect on the patient, serious adverse events not related to the device, mortality, and unanticipated adverse device effects
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Frédéric Anselme, MD, CHU Charles Nicolle - Rouen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2004
Primary Completion (ACTUAL)
October 1, 2007
Study Completion (ACTUAL)
October 1, 2007
Study Registration Dates
First Submitted
April 7, 2008
First Submitted That Met QC Criteria
June 30, 2008
First Posted (ESTIMATE)
July 2, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
July 2, 2008
Last Update Submitted That Met QC Criteria
June 30, 2008
Last Verified
June 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ITAC01-VISION
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Apnoea
-
Papworth Hospital NHS Foundation TrustIceni Labs Ltd, Warwickshire, United KingdomCompletedObstructive Sleep Apnoea | Sleep ApnoeaUnited Kingdom
-
Heart and Diabetes Center North-Rhine WestfaliaCompletedObstructive Sleep Apnoea | Cheyne Stokes Respiration | Central Sleep ApnoeaGermany
-
University of CreteCompleted
-
University of ZurichCompletedObstructive Sleep ApnoeaSwitzerland
-
University of British ColumbiaCompleted
-
ResMedCompletedObstructive Sleep Apnoea (OSA)Australia
-
ResMedCompleted
-
Imperial College London Diabetes CentreUnknown
-
Air Liquide Santé InternationalClinactRecruitingObstructive Sleep Apnoea Syndrome (OSAS)Portugal
-
University of MalayaUnknownObstructive Sleep ApnoeaMalaysia
Clinical Trials on ICD
-
Barts & The London NHS TrustCompletedHeart FailureUnited Kingdom
-
Wuerzburg University HospitalUniversity of Leipzig; University of Wuerzburg; Campus Bad Neustadt; Klinikum Aschaffenburg-Alzenau and other collaboratorsCompletedDepression | Quality of Life | AnxietyGermany
-
Boston Scientific CorporationCompletedTachycardia, VentricularUnited Kingdom, Denmark, Italy, New Zealand, Germany, France, Netherlands, Portugal, Czechia, Spain
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceRecruitingHeart Failure | Implantable Cardioverter Defibrillator | Primary Prevention of Sudden Cardiac DeathFrance
-
Biotronik, Inc.CompletedPatients Indicated for an ICDUnited States
-
Biotronik SE & Co. KGCompletedHeart Failure | TachyarrhythmiaDenmark, France, Germany, Spain, Switzerland, Israel, Latvia, Australia, Singapore, Austria
-
Medtronic Bakken Research CenterMedtronicCompletedTachycardia, VentricularGermany, Denmark
-
Unity Health TorontoApplied Health Research Centre; Biotronik Canada IncActive, not recruitingCardiovascular Diseases | Implantable Cardioverter-Defibrillators | Cardiac Arrhythmias | Atrial Fibrillation and FlutterCanada
-
Vanderbilt University Medical CenterThoratec CorporationCompleted
-
Boston Scientific CorporationCompletedVentricular Fibrillation | Ventricular TachycardiaUnited Kingdom